Find Clinical Trials
Early treatment of Idiopathic Parkinson’s Disease (IPD) with dopaminergic agonist piribedil in monotherapy (adaptation of the daily dose from 150 to 300 mg per day per os). A 2-year randomised, parallel group, placebo controlled study in IPD “de novo” patients.
Servier Protocol Code:
CL3-04200-006
Sponsor:
Institut de Recherches Internationales Servier (I.R.I.S)
Find a recruiting site
Name:
Institut de Recherches Internationales Servier, Département des études cliniques
Phone number:
+33 1 55 72 60 00
Results
English (USA)Interventions / Treatments
The treatment(s) given to the participants in the study.
- Parkinson's disease
- PIRIBEDIL
- S004200
Other study id numbers
Other identification numbers the study may be known by.
- CL3-04200-006